181 related articles for article (PubMed ID: 30774762)
1.
Terzo EA; Lim AR; Chytil A; Chiang YC; Farmer L; Gessner KH; Walker CL; Jansen VM; Rathmell WK
Oncotarget; 2019 Jan; 10(6):647-659. PubMed ID: 30774762
[TBL] [Abstract][Full Text] [Related]
2. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.
Feng C; Ding G; Jiang H; Ding Q; Wen H
Tumour Biol; 2015 May; 36(5):3457-64. PubMed ID: 25528216
[TBL] [Abstract][Full Text] [Related]
3. PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.
Feng C; Sun Y; Ding G; Wu Z; Jiang H; Wang L; Ding Q; Wen H
Sci Rep; 2015 Apr; 5():9465. PubMed ID: 25853938
[TBL] [Abstract][Full Text] [Related]
4. High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.
Wang J; Wen J; Yi R; Liu F; Zhou J; Liu G; Li Q; Yang Z; Su X
J BUON; 2015; 20(5):1267-75. PubMed ID: 26537074
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.
Xu W; Berning P; Erdmann T; Grau M; Bettazová N; Zapukhlyak M; Frontzek F; Kosnopfel C; Lenz P; Grondine M; Willis B; Lynch JT; Klener P; Hailfinger S; Barry ST; Lenz G
Leukemia; 2023 Jan; 37(1):178-189. PubMed ID: 36352190
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
7. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.
Maynard J; Emmas SA; Blé FX; Barjat H; Lawrie E; Hancox U; Oakes D; Polanska UM; Barry ST
EJNMMI Res; 2016 Dec; 6(1):62. PubMed ID: 27515445
[TBL] [Abstract][Full Text] [Related]
8. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract][Full Text] [Related]
9. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
Owusu-Brackett N; Zhao M; Akcakanat A; Evans KW; Yuca E; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2020 Mar; 11(11):969-981. PubMed ID: 32215185
[No Abstract] [Full Text] [Related]
10. Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Lynch JT; Polanska UM; Delpuech O; Hancox U; Trinidad AG; Michopoulos F; Lenaghan C; McEwen R; Bradford J; Polanski R; Ellston R; Avivar-Valderas A; Pilling J; Staniszewska A; Cumberbatch M; Critchlow SE; Cruzalegui F; Barry ST
Clin Cancer Res; 2017 Dec; 23(24):7584-7595. PubMed ID: 28972046
[No Abstract] [Full Text] [Related]
11. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.
Ruiz de Porras V; Bernat-Peguera A; Alcon C; Laguia F; Fernández-Saorin M; Jiménez N; Senan-Salinas A; Solé-Blanch C; Feu A; Marín-Aguilera M; Pardo JC; Ochoa-de-Olza M; Montero J; Mellado B; Font A
Front Pharmacol; 2024; 15():1331648. PubMed ID: 38318136
[No Abstract] [Full Text] [Related]
13. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.
Zhang Z; Liu J; Wang Y; Tan X; Zhao W; Xing X; Qiu Y; Wang R; Jin M; Fan G; Zhang P; Zhong Y; Kong D
FASEB J; 2018 Nov; 32(11):5967-5975. PubMed ID: 29792732
[TBL] [Abstract][Full Text] [Related]
15. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
17. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
18. Loss of SETD2-mediated downregulation of intracellular and exosomal miRNA-10b determines MAPK pathway activation and multidrug resistance in renal cancer.
Yan L; Liu S; Sun G; Ding B; Wang Z; Li H
Mol Carcinog; 2023 Nov; 62(11):1770-1781. PubMed ID: 37589422
[TBL] [Abstract][Full Text] [Related]
19. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
[TBL] [Abstract][Full Text] [Related]
20. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]